Patrick Yang

Andeavor engages in the refining and marketing of petroleum products. It operates through the following segments: Refining, Logistics, and Marketing. The Refining segment buys and refines crude oil and other feed stocks into transportation fuels, such as gasoline and gasoline blend stocks, jet fuel and diesel fuel, as well as other products, including heavy fuel oils, liquefied petroleum gas and petroleum coke for sale in bulk markets to a wide variety of customers within Andeavor's markets. The logistics segment includes crude oil and natural gas gathering assets, natural gas and natural gas liquid processing assets, and crude oil and refined products terminalling, transportation and storage assets acquired from Andeavor and third parties. The Marketing segment sells transportation fuels through branded and unbranded channels. Its brand portfolio includes ARCO, Shell, Exxon, Mobil, USA Gasoline, Rebel, and Tesoro. The company was founded by West V. Robert, Jr. in 1964 and is headquartered in San Antonio, TX.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA.

Life Systems Corp. is a biotech company, which researches, develops and sells organ preservation device technology. The company was founded by Fereydoon Sadri in 1994 and is headquartered in Redmond, WA.

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan.

Tetra Tech Tesoro, Inc. provides construction services. It also build schools, hospitals, and clinics for selected commercial and private clients. The company was founded on June 4, 1997 and is headquartered in Virginia Beach, VA.

Archigen Biotech Ltd. is a British company that develops, manufactures, and distributes biological pharmaceuticals. Archigen Biotech is based in Cambridge, UK. The joint venture company was founded in 2014.

National Resilience, Inc. is a biopharmaceutical manufacturing and technology company, which engages in the development of vaccines. It offers virus production, formulations, RNA modalities, and CMC development. The company was founded in 2020 and is headquartered in La Jolla, CA.

Antheia, Inc. provides supply of plant-based medicines and to transform the discovery, manufacture, and distribution of medicines. The company was founded by Kristy Hawkins, Christina Smolke, Kate Thodey, and Isis Trenchard. The company is headquartered in Menlo Park, CA.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

Polaris Pharmaceuticals, Inc. researches and develops protein drugs for cancer treatment. It offers ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma; Uricase-PEG 20; TNF-PEG 20 and CK2 inhibitor. Polaris Pharmaceuticals was founded in 2006 and is headquartered in San Diego, CA.